NSW Peptide Emergency-Department Presentations: What 1,180 Visits Show

NSW Health recorded 1,180 emergency-department presentations mentioning unapproved peptide use between 1 July 2025 and 30 September 2026. The surveillance covered unplanned visits by people aged 16 and over at 88 reporting public-hospital emergency departments. The underlying report gives monthly counts of five in July 2025 and 217 in September 2026.

This is a substantial surveillance signal. It counts presentations, including repeat visits, rather than verified cases of poisoning or a count of unique people. Read the NSW Health report.

Sources checked: 20 October 2026. This article interprets public surveillance and regulatory records. The source-check date does not imply medical review.

What do the NSW figures measure?

The method searches triage documentation for relevant terms. NSW Health identifies incomplete capture, possible misclassification and changes in recording practices. A mention can concern previous use, and the record does not establish that a peptide caused the visit or any subsequent admission.

These are emergency-department presentations. Describing the total as “1,180 hospitalisations caused by peptides” would change both the measured event and the strength of the causal claim.

Which product names appear in the warning?

The 19 October NSW Health media release names products claiming to contain BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295. NSW Health states that these peptides are not currently approved in Australia for any purpose. A reported label name does not chemically identify the material involved.

The release also describes monitoring through poison-information calls and clinician reports, including serious liver and kidney illness. Those additional reports should not be treated as diagnoses confirmed in every presentation in the surveillance total.

NSW Health’s peptide-products guidance explains that professional packaging, reviews and influencer endorsements cannot establish a product’s contents or safety. Different batches carrying the same label can differ in ingredients or strength.

What can the rising trend tell us?

The data give health authorities a reason to investigate a changing pattern. They do not supply the denominator needed to calculate the chance of an adverse event per user or per exposure. This report therefore cannot rank the named compounds by individual risk, estimate population incidence or compare their risk directly with a registered medicine used in a different population.

That distinction matters when interpreting a safety signal. Detecting a pattern, checking the identity of a product and establishing causation are different steps. Uncertainty about causation does not make the observed pattern unimportant; it defines the further evidence needed.

Why purity, identity and approval are separate questions

A dominant chromatographic peak describes a detector signal under a method. It does not establish every quality attribute of a finished product. Our HPLC interpretation guide and HPLC versus mass spectrometry comparison explain the limits of analytical reports.

The TGA’s peptide-products guidance distinguishes approved medicines from unapproved products that have not undergone its assessment of safety, quality and effectiveness. A research label, a trial registration and a laboratory result each answer different questions from an Australian product approval.

For the Australian framework, see our regulation guide. For the earlier tested-sample case, see the September retatrutide alert briefing. Neither a single sample result nor this surveillance total establishes the contents of every product bearing a familiar molecule name.

Sources and scope

1. NSW Health surveillance report: summary, methods and limitations, pages 1, 2 and 5.
2. NSW Health media release, 19 October 2026.
3. NSW Health: peptide products.
4. TGA: peptide products.

Compound subgroup percentages are omitted because the report’s category wording leaves an unresolved overlap. This article provides evidence interpretation, without individual treatment or product-use instructions.